FDA approves 1st oral drug for rare autoimmune disease

The FDA has approved Lisraya (brepocitinib) tablets for adults with dermatomyositis, marking the first FDA-approved oral treatment for the rare autoimmune disease. The approval was based on a phase 3 randomized, double-blind, multicenter, placebo-controlled study involving 241 adults, according to an Aug. 27 news release. Participants received Lisraya 30 milligram once daily, brepocitinib 15 milligram […] The post FDA approves 1st oral drug for rare autoimmune disease appeared first on Bec...